Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifaximin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 2/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifaximin SCHEMBL16351426 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124066 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL16229249 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL874028 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL14677545 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL13897021 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL23314507 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL17930616 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124067 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL11956496 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2870163-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN AND AMINO ACIDS, PREPARATION METHOD AND USE THEREOF | ALFASIGMA SPA (IT) | 2018-09-19 | — | — | EP | disclosed |
| US-20170189385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN AND AMINO ACIDS, PREPARATION METHODS AND USE THEREOF | ALFA WASSERMANN S.P.A. (IT) | 2017-07-06 | — | — | US | disclosed |
| EP-3160467-A1 | METHODS FOR RETREATING IRRITABLE BOWEL SYNDROME (IBS) | Salix Pharmaceuticals, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3143027-A1 | NEW SOLVATED CRYSTAL FORM OF RIFAXIMIN, PRODUCTION, COMPOSITIONS AND USES THEREOF | ALFA WASSERMANN S.p.A. (IT) | 2017-03-22 | — | — | EP | disclosed |
| EP-3127909-A1 | CRYSTALLINE FORMS OF RIFAXIMIN AND THEIR PREPARATION IN THE PRESENCE OF AMINO ACIDS | ALFA WASSERMANN S.p.A. (IT) | 2017-02-08 | — | — | EP | disclosed |
| US-9452157-B2 | Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof | ALFA WASSERMANN S.P.A (IT) | 2016-09-27 | — | — | US | disclosed |
| WO-2016003536-A1 | METHODS FOR RETREATING IRRITABLE BOWEL SYNDROME (IBS) | SALIX PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015173697-A1 | NEW SOLVATED CRYSTAL FORM OF RIFAXIMIN, PRODUCTION, COMPOSITIONS AND USES THEREOF | ALFA WASSERMANN S.P.A. (IT) | 2015-11-19 | — | — | WO | disclosed |
| US-20140079783-A1 | Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof | ALFASIGMA S.P.A. (IT) | 2014-03-20 | — | — | US | disclosed |
| CN-103118666-A | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease | ALFA WASSERMANN SPA | 2013-05-22 | — | — | CN | disclosed |
| US-5352679-A | OraL administering | ALFA WASSERMANN S.P.A. (IT) | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079783-A1 | Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof | RIF1, MLX, SFXN1 | ABCB11 214/4885ABCC4 3546/4885ABCC2 3083/4885 |
| US-20170189385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN AND AMINO ACIDS, PREPARATION METHODS AND USE THEREOF | RIF1, MLX, SFXN1 | ABCB11 214/4885ABCC4 3546/4885ABCC2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.